Archive: June 2024

Antibody-Drug Conjugates in Advanced Lung Cancer: Is This a New Frontier?

Abstract: Over the past decade, the lung cancer landscape has been dominated by targeted and immunotherapeutic approaches that have drastically shifted treatment paradigms for patients with […]

Redefining the Standard of Care for Low-Grade Serous Ovarian Cancer

Abstract: Low-grade serous carcinoma is a rare epithelial ovarian cancer subtype with distinct clinical, histologic, and molecular features. Improved understanding of this disease subtype has prompted […]

The Evolving Role of Surgery in Melanoma

H&O  What has been the traditional role of surgery in melanoma? VKS  Surgery has long been the mainstay of treatment for all early-stage melanomas. We used […]

Pirtobrutinib in Relapsed or Refractory CLL and SLL

H&O  What are the mechanisms of action of pirtobrutinib and other Bruton tyrosine kinase (BTK) inhibitors? JW  All of the currently available BTK inhibitors work by […]

New Drug Approvals for Prostate Cancer

H&O  What are the most recent drug approvals for prostate cancer? IT  The most recent drug approvals for men with prostate cancer primarily consist of “me-too” […]

STEAP1 as a Potential Target for New Therapies in Prostate Cancer

H&O What is six-transmembrane epithelial antigen of prostate 1 (STEAP1)? WKK STEAP1 was first described more than 2 decades ago. It is a cell-surface antigen that […]

Back to Archive